TrDizin

Permanent URI for this collectionhttps://hdl.handle.net/11452/21452

Browse

Browsing by Author "0000-0001-5757-8450"

Filter results by typing the first few letters
Now showing 1 - 1 of 1
  • Thumbnail Image
    Item
    Investigation of neuroprotective effects of cyclooxygenase inhibitors in the 6-hydroxydopamine induced rat Parkinson model
    (Türk Nöroşurji Derneği, 2009-07) Gören, Bülent; Mimbay, Zehra; Bilici, Nebahat; Zarifoğlu, Mehmet; Oğul, Erhan; Korfalı, Ender; Uludağ Üniversitesi/Tıp Fakültesi/Fizyoloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Histoloji ve Embriyoloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Nöroloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Nöroşirürji Anabilim Dalı.; 0000-0001-5757-8450; AAH-1718-2021; ABC-1475-2020; 6602543716; 35092977400; 35092119200; 6603411305; 6603268541; 7004641343
    AIM: Recent experimental and clinical studies on Parkinson's disease point out the pivotal role of inflammation in the pathogenesis of neurodegeneration and the possible positive effects of nonsteroidal anti-inflammatory drug therapies. Our aim in this study was to investigate the preventive effects of nonsteroidal anti-inflammatory drugs in the 6-hydroxydopamine (6-OHDA) induced rat model of Parkinson's disease. MATERIAL and METHODS: Twenty-one female Wistar-Albino rats (200-250g) were used in this study. The rats were divided in three groups: Saline group (n: 7, 2 ml), Acetylsalicylic acid group (n: 7, 100 mg/kg), and Meloxicam group (n: 7, 50 mg/kg). An hour after administration, the rats received a unilateral intranigral injection of 6-OHDA to produce the Parkinson model lesion. Rotational tests were performed two weeks later as follow-up. Immunohistochemical tests were performed in all groups to determine the severity of the lesion in the substantia nigra. RESULTS: Administration of drugs an hour before the lesions were created did not protect the degeneration of dopaminergic neurons in the substantia nigra. CONCLUSION: Oral usage of low repeated doses of nonsteroidal anfi-inflammatory drugs may possibly slow down the progression of the disease.